The project is part of Europe's EuResist program.
IBM Corp. (NYSE: IBM) is expanding its range of medical solutions for the treatment of AIDS. Researchers at the company's Haifa Research Lab are taking part in an EU project called EuResist, which is focusing on the development of a clinical management system for the use of drugs given to AIDS patients and carriers to prevent the reproduction of the HIV virus. IBM says the system will provide the clinicians with a prediction of response to antiretroviral treatment in HIV patients, thus helping the clinicians to choose the best drugs and drug combinations for any given HIV genetic variant and improve the treatment's efficiency.
The EuResist project is part of the EU's 6th Framework Programme for Innovation (the seventh was launched this year), and IBM Haifa is one of the project partners together with universities and drug companies across Europe. The project is using IBM's tools to coordinate the development and testing of the different predictive models for the HIV virus. The project's data base has records on more than 17,000 patients.
Published by Globes [online], Israel business news - www.globes.co.il - on October 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007